Upcoming Clinical Trials At Triple O Research

Below Are a list of Clinical Trials at Triple O Research. To Participate In one of these trials simply click on the Trial Header To Access Information from ClinicalTrials.Gov


Rank Status Study
1 Active, not recruiting Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus

Condition: HIV-1 Infection
Interventions: Drug: Cenicriviroc 100 mg;   Drug: Cenicriviroc 200 mg + Truvada;   Drug: Sustiva + Truvada
2 Active, not recruiting BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C

Condition: Hepatitis C
Interventions: Drug: BMS-790052 (NS5A Replication Complex Inhibitor);   Drug: Peg-Interferon Alfa-2a;   Drug: Ribavirin
3 Completed Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects

Condition: HIV Infections
Intervention: Drug: elvucitabine
4 Completed Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1

Condition: HIV
Intervention: Drug: Ibalizumab
5 Completed Study of KP-1461 for the Treatment of HIV Positive Patients Who Have Failed Multiple HAART Regimens

Condition: HIV Infections
Intervention: Drug: KP-1461
6 Completed Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients

Condition: HIV Infections
Intervention: Drug: miconazole Lauriad
7 Recruiting Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

Condition: HIV-1 Infection
Interventions: Drug: BMS-986001;   Drug: Placebo matching with BMS-986001;   Drug: Efavirenz;   Drug: Lamivudine;   Drug: Tenofovir
8 Recruiting Atazanavir/Ritonavir (ATV/RTV) Once a Day (QD) + Raltegravir (RAL) Twice a Day (BID) Stable Switch Study

Condition: HIV, Combination Therapy
Interventions: Drug: Atazanavir;   Drug: Ritonavir (heat-stable);   Drug: Raltegravir;   Drug: Tenofovir/Emtricitabine
9 Active, not recruiting A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Ixabepilone (Ixempra);   Drug: Paclitaxel (Taxol)
10 Recruiting Re-expression of ER in Triple Negative Breast Cancers

Conditions: Breast Cancer;   Breast Tumors;   Breast Neoplasms
Intervention: Drug: Decitabine, LHB589, Tamoxifen
11 Active, not recruiting Triple Negative Breast Cancer Biomarker Study

Conditions: Metastatic Breast Cancer;   Triple Negative Breast Cancer
Intervention:
12 No longer available An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.

Condition: HIV Infections
Intervention: Drug: Tipranavir
13 Completed TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients

Condition: Influenza
Interventions: Drug: TCAD;   Drug: Zanamivir or Oseltamivir;   Other: Open label treatment with TCAD
14 Unknown  The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy

Condition: Helicobacter Pylori
Intervention: Drug: FP-10
15 Active, not recruiting A Clinical Trial to Study the Effects of Revamilast in Patients With Chronic Persistent Asthma

Condition: Asthma
Interventions: Drug: Revamilast;   Drug: Placebo
16 Active, not recruiting Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients

Condition: Breast Cancer
Intervention: Drug: Capecitabine
17 Active, not recruiting Efficacy and Safety of DEB025 Combined With Peg-IFN Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Relapsers and Non-responders

Condition: Hepatitis C Chronic
Interventions: Drug: DEB025 600 mg QD + SOC;   Drug: DEB025 800 mg QD;   Drug: placebo + SOC;   Drug: DEB025 400 mg BID + SOC
18 Completed A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: Revamilast;   Drug: Placebo Comparator
19 Completed Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: Drug: Placebo 0.01 mL;   Drug: Placebo 0.02 mL;   Drug: Placebo 0.03 mL;   Drug: Placebo 0.04 mL;   Drug: AC2993 2.5 mcg;   Drug: AC2993 5.0 mcg;   Drug: AC2993 7.5 mcg;   Drug: AC2993 10.0 mcg
20 Completed The Effect of Teaching HIV-Infected Patients About HIV and Treatment

Condition: HIV Infections
Interventions: Drug: Lamivudine/Zidovudine;   Drug: Abacavir sulfate